Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (861-870 of 903) with videos related to

Pageof 91
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 13, 2019
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
Nature|February 17, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingA A Alizadeh, M B Eisen, R E Davis, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Blood Advances|July 5, 2022
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AMLKarilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Blood Cancer Discovery|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Blood Cancer Discovery|November 5, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic LeukemiaBritten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Pageof 91

Showing results (861-870 of 903) with videos related to

Sort By:
Pageof 91
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 13, 2019
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host diseaseKatelyn Paz, Ryan Flynn, Jing Du, et al.
The Journal of Clinical Investigation|October 2, 2014
Ibrutinib treatment ameliorates murine chronic graft-versus-host diseaseJason A Dubovsky, Ryan Flynn, Jing Du, et al.
Nature|February 17, 2000
Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingA A Alizadeh, M B Eisen, R E Davis, et al.
Blood|July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesJason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Blood Advances|July 5, 2022
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AMLKarilyn T Larkin, Deedra Nicolet, Benjamin J Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Blood Cancer Discovery|May 20, 2026
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Blood Cancer Discovery|November 5, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic LeukemiaBritten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Pageof 91